RGBP Regen BioPharma Inc
Pharmaceutical Preparations · OTC · SEC CIK 1589150 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.0%
TTM net income YoY-54.5%
TTM EPS YoY77.8%
Revenue 3-yr CAGR15.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-339.8%
Net margin-501.4%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-489.7%
ROIC (approx.)—
Asset turnover0.98x
Leverage & solvency
Liabilities / assets2,144.0%
Debt / equity—
Current ratio0.05x
Interest coverage-4.72x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-305.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 | FY20232023-09-30 | FY20222022-09-30 | FY20212021-09-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $236,561 | $236,560 | $236,560 | $125,517 | $61,194 |
| R&D expense | $11,725 | $153,685 | $212,297 | $158,138 | $36,704 |
| SG&A expense | $75,113 | $58,920 | $44,975 | $28,055 | $119,495 |
| Operating income | -$338,540 | -$417,221 | -$686,950 | -$339,605 | -$200,771 |
| Interest expense | $158,286 | $72,445 | $58,584 | $138,720 | $316,013 |
| Pretax income | -$1.27M | -$668,255 | $1.16M | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$1.27M | -$668,255 | $1.16M | $2.44M | -$6.77M |
| EPS (basic) | -0.05 | -0.16 | 0.29 | 0.71 | -0.00 |
| EPS (diluted) | -0.05 | -0.16 | 0.29 | 0.71 | -0.00 |
| Weighted avg. shares (diluted) | 23.52M | 4.11M | 3.54M | 3.14M | — |
| Banking | |||||
| Net interest income | — | — | — | $455 | $230 |
| Balance sheet | |||||
| Cash & equivalents | $69,555 | $716 | $121,037 | $51,204 | $727,162 |
| Receivables | $204,873 | $94,873 | $0 | $254,273 | $213,192 |
| Current assets | $274,628 | $143,351 | $131,037 | $336,422 | $994,124 |
| Total assets | $274,628 | $161,084 | $353,617 | $559,002 | $1.21M |
| Current liabilities | $6.56M | $5.38M | $5.31M | $8.60M | $14.70M |
| Total liabilities | $6.56M | $5.38M | $5.46M | $8.60M | $14.70M |
| Shareholders' equity | -$6.28M | -$5.22M | -$5.10M | -$8.04M | -$13.49M |
| Shares outstanding | 39.37M | 5.26M | 3.51M | 3.35M | 4.35B |
| Cash flow statement | |||||
| Operating cash flow | -$383,591 | -$751,536 | -$173,917 | -$606,921 | -$1.13M |
| Investing cash flow | — | — | — | $25,000 | $495,000 |
| Financing cash flow | $452,430 | $631,215 | $243,750 | -$94,036 | $1.36M |
| Stock-based compensation | — | $13,048 | $348,372 | — | — |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.